A study conducted at the University of Texas has discovered that combination therapy may be a viable treatment for cholangiocarcinoma with BRAF mutations. Researchers treated participants with both dabrafenib and…
According to a story from curetoday.com, Dr. Tara Seery is an investigator in a phase 3 trial called PROOF, and she has just one goal: finding better treatments for cholangiocarcinoma,…
BridgeBio Pharmaceuticals has recently announced that their drug, infigratinib, has received the Fast Track and Orphan Drug designations from the FDA. This drug is meant for the treatment of…
.jpg)
Health News Digest recently published an article that describes a simple blood test called DELFI, meaning DNA evaluation of fragments for early interception. Its simplicity belies the fact that it can detect…
© Copyright Patient Worthy
